Table 4. SAEs within 3 months of MDA in villages with early MDA compared to control villages with deferred MDA for the first 12 months.
| SAE | Within 3 months | Within 12 months | ||||
|---|---|---|---|---|---|---|
| MDA villages (n = 4,135) |
Control villages (n = 2,596*) |
Total | MDA villages (n = 4,135) |
Control villages (n = 2,596*) |
Total | |
| Death (without diagnosis of underlying disease) | 2 | 0 | 2 | 10 | 5 | 15 |
| Life-threatening illness | 2 | 1 | 3 | 11 | 3 | 14 |
| Debilitating disease due to old age | 0 | 0 | 0 | 1 | 0 | 1 |
| Hospitalisation due to pneumonia | 2 | 0 | 2 | 2 | 0 | 2 |
| Drowning | 0 | 0 | 0 | 0 | 2 | 2 |
| Suicide | 0 | 0 | 0 | 2 | 0 | 2 |
| Gastric cancer | 0 | 0 | 0 | 1 | 0 | 1 |
| Prolongation of hospitalisation | 0 | 0 | 0 | 1 | 0 | 1 |
| Total SAEs | 6 (0.15%) | 1 (0.04%) | 7 | 28 (0.7%) | 10 (0.39%) | 38 |
p = 0.187 and 0.120 for comparison of number of SAEs between early MDA and control villages within 3 months and within 12 months, respectively.
*No recorded data from Lao People’s Democratic Republic and Cambodia in control villages.
MDA, mass drug administration; SAE, serious adverse event.